## Confirmation No. 5347

Date

Customer No. 28880 PTO/SB/21 (09-04) Approved for use through 07/31/2008. OMB 0851-40031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE tion of information unless it displays a valid OMR control number Inder the Paperwork Reduction Act of 1995, no persons are required to respond to Application Number 10/828,419 RECEIVED TRANSMITTAL Filing Date April 20, 2007 First Named Inventor CENTRAL PAX CENTER **FORM** Berchielli, et al. Art Unit 1615 Examiner Name Ahmed, Hasan Syed (to be used for all correspondence after initial filing) Attorney Docket Number PC25684A Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Drawing(s) Fee Transmittal Form Anneal Communication to Board Licensing-related Papers Fee Attached of Appeals and Interferences Appeal Communication to TC **✓** Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a Proprietary Information Provisional Application After Final Power of Attorney, Revocation Status Letter Change of Correspondence Address Affidavits/declaration(s) Other Enclosure(s) (please Identify Terminal Disclaimer below): Extension of Time Request Request for Refund Express Abandonment Request CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Authorization to charge the fee and any additional fees as necessary or credit Reply to Missing Parts/ any overpayment to Deposit Account 16-1445 is hereby given. Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Pfizer Inc. Signature Printed name Steven R. Eck Date 36,126 2007 CERTIFICATE OF TRANSMISSION/MAILING nereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature

This collection of information is required by 37 CFR 1,5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case, Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22312-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

USPTO Fax No.

Typed or printed name

571-273-8300

Cynthia Bernges

RECEIVED CENTRAL FAX CENTER

## UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 2 9 2007

Application No.:

10/828,419

Confirmation No.:

5347

Applicants:

Alfred Berchielli, et al.

Filed:

April 20, 2004

TC/A.U.:

1615

Examiner:

Hasan Syed Ahmed

Docket No.:

PC25684A

Customer No.:

28880

For:

PHARMACEUTICAL COMPOSITIONS OF ATORVASTATIN

Commissioners for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## AMENDMENT AND RESPONSE

## Dear Sir:

The amendments and remarks herein are in response to the Office Action mailed on March 30, 2007, Applicants make the following remarks. Claims 1-30 are pending in the present application, Claims 18-30 have been withdrawn from consideration, Claims 1-7 and 12-17 are rejected and Claims 8-11 have been objected to.

Amendments to the Claims begin on page 2 of this paper.

Remarks/Arguments begin on page 7 of this paper.